Again FDA emphasises Importance of written Contracts
Recommendation
2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
End 2016, the US Food and & Administration (FDA) published its long awaited final Guidance on Contract Manufacturer Quality Agreements.
The authority recommends that quality agreements should contain the following sections at a minimum:
- purpose and scope of the agreement
- terms of the agreement, including its effective dates
- terms for dispute resolution
- responsibility of each respective party
- change control and revision practices
And the agency takes things seriously. In a recent Warning Letter from March 2018, the FDA again refers to Quality Agreements and the respective guidance: "FDA is aware that many pharmaceutical product manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer." In their relationship with a customer, they recommend the addressee (Tris Pharma Inc.), to have a look at FDA's guidance document.
For further information please see the FDA Warning Letter to Tris Pharma Inc.
Related GMP News
17.08.2026Why Root Cause Analysis is the Key to efficient CAPA
17.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
17.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?
15.07.2026Root Cause Analysis and CAPA: Two more Warning Letters issued to Companies in Europe